The FY2016 Earnings Estimate for Alnylam Pharmaceuticals Inc. (ALNY) Issued By FBR & Co

The FY2016 Earnings Estimate for Alnylam Pharmaceuticals Inc. (ALNY) Issued By FBR & Co

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) – Stock analysts at FBR & Co upped their FY2016 earnings per share estimates for Alnylam Pharmaceuticals in a research note issued on Thursday. FBR & Co analyst C. James now expects that the firm will post earnings of ($3.82) per share for the year, up from their prior estimate of ($4.11). FBR & Co currently has a “Outperform” rating and a $100.00 target price on the stock. FBR & Co also issued estimates for Alnylam Pharmaceuticals’ Q4 2016 earnings at ($0.48) EPS, FY2017 earnings at ($3.13) EPS, FY2018 earnings at ($2.73) EPS, FY2019 earnings at ($0.34) EPS and FY2020 earnings at $4.45 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. The company earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.85) earnings per share.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, July 25th. Jefferies Group reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 30th. JMP Securities reiterated a “buy” rating and issued a $127.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 23rd. Leerink Swann reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 19th. Finally, Chardan Capital reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, July 11th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $79.50.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 34.83 on Monday. Alnylam Pharmaceuticals has a one year low of $33.16 and a one year high of $110.75. The stock has a 50 day moving average of $68.44 and a 200 day moving average of $65.73. The stock’s market cap is $2.99 billion.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.00% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $128,000. Janney Montgomery Scott LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $223,000. Seven Eight Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $175,000. Finally, BlueMountain Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Related posts

Leave a Comment